DMSO Does Not Help Restless Legs Syndrome
DMSO (dimethyl sulfoxide) is not recommended for treating restless legs syndrome and has no evidence supporting its use for this condition. The most recent and comprehensive 2025 American Academy of Sleep Medicine (AASM) clinical practice guidelines for RLS treatment make no mention of DMSO among the 22 specific treatment recommendations reviewed 1.
Why DMSO Is Not Appropriate for RLS
FDA-Approved Indication Is Unrelated
The FDA has approved DMSO for only one indication: symptomatic relief of interstitial cystitis (bladder condition), administered via intravesical instillation 2. The FDA label explicitly states: "RIMSO-50® has not been approved as being safe and effective for any other indication" 2.
No Evidence Base for RLS
- DMSO has been studied primarily for musculoskeletal conditions including osteoarthritis, complex regional pain syndrome, and post-traumatic swelling 3, 4, 5, 6
- The mechanism of action (oxygen-free radical scavenging, anti-inflammatory effects, enhanced drug penetration through skin) does not address the underlying pathophysiology of RLS, which involves dopaminergic dysfunction and iron deficiency 7, 8
- No clinical trials have evaluated DMSO for RLS treatment
Safety Concerns
The FDA label warns of significant adverse effects that make DMSO particularly problematic 2:
- Lens opacities and refractive changes seen in animal studies requiring periodic slit lamp eye examinations
- Requires biochemical screening every 6 months (liver, renal function, complete blood count)
- Potentiates other concomitantly administered medications - a critical concern since RLS patients often require multiple medications
- Teratogenic in animal studies at high doses
- Not established as safe in children
Evidence-Based RLS Treatment Algorithm (2025 AASM Guidelines)
First-Line Treatments (Strong Recommendations)
- Gabapentin or pregabalin - strongest evidence for efficacy 1
- IV ferric carboxymaltose for patients with appropriate iron parameters (ferritin <75 μg/L or ferritin 75-100 μg/L with transferrin saturation <20%) 1
Second-Line Options (Conditional Recommendations)
- Oral ferrous sulfate for appropriate iron status 1
- Extended-release oxycodone and other opioids 1
- Dipyridamole 1
- Bilateral high-frequency peroneal nerve stimulation 1
Treatments to AVOID or Use Only Short-Term
The 2025 guidelines now recommend against standard use of dopamine agonists (pramipexole, ropinirole, rotigotine) due to augmentation risk - a progressive iatrogenic worsening of RLS 1, 8. These may only be considered for short-term use in patients who prioritize immediate symptom relief over long-term adverse effects.
Clinical Pitfall
Do not be misled by DMSO's use as a pharmaceutical solvent in some cancer therapies 9 or its off-label use for pain conditions 10, 3. The absence of DMSO from authoritative RLS treatment guidelines, combined with its narrow FDA approval and significant safety monitoring requirements, makes it an inappropriate choice for RLS management.